Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated with GLP1 therapy, which the analyst calls ...

The university claims using the logo in the scene "simply goes too far." By Lexi Carson [The following story contains spoilers from the latest episode of The White Lotus, “Denials.”] After an ...

Hello, everyone, and welcome to Allurion Fourth Quarter Earnings Call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question-and-answer session.

Allurion Technologies, Inc. (ALUR) came out with a quarterly loss of $7 per share versus the Zacks Consensus Estimate of a loss of $5. This compares to loss of $15.75 per share a year ago.

Fourth Quarter Revenue: $5.6 million. Full-Year Revenue: $32.1 million. Operating Expenses: Decreased by 39% in Q4 compared to the prior year. Procedure Volumes: Grew by 4% in 2024. Gross Profit ...

Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo. The data showed improved lean body mass and full ...

Hello, everyone, and welcome to Allurion fourth quarter earnings call. Please note that this call is being recorded. After the speaker's prepared remarks, there will be a question and answer session. ...

SPOILERS: This post contains details about the White Lotus, Season 3 episode ‘Denials’ As this season of The White Lotus continues to push the limits of Mike White’s imagination, a ...

Fourth Quarter Revenue: $5.6 million. Full-Year Revenue: $32.1 million. Operating Expenses: Decreased by 39% in Q4 compared to the prior year. Procedure Volumes: Grew by 4% in 2024. Gross Profit (Q4 ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical company focused on obesity treatment currently trading near its 52-week low at $2.27, has announced promising initial results ...